Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
There are five approved biosimilars for Eylea - Amgen's Pavblu, Sandoz's Enzeevu, Formycon's Ahzantive, Samsung Bioepis' Opuviz and Biocon Biologics' Yesafili. Alvotech is also developing AVT29 ...
The cardiometabolic franchise is expected to expand and entrench its market position. Pavblu, Amgen’s Eylea biosimilar, is well-positioned to compete effectively due to injunctions against other ...